Varian

The companies will integrate DNAmito's Prodecis into Varian's 360 Oncology care management software to deliver genomics-based evidence to guide radiation therapy in cancer.

The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.

NEW YORK (GenomeWeb) – Agilent Technologies announced today that it is exiting the nuclear magnetic resonance market, saying that its business in this area "has not met growth and profitability objectives."

CEO Bill Sullivan cited the 1290 Infinity LC and the recently introduced 1260 Infinity and 1220 Infinity platforms as drivers of the company's liquid chromatography business.

The rating agency raised its outlook on Agilent to 'positive' from 'stable' due to "greater confidence in Agilent's operating and financial profile."

The company made the disclosures as part of Agilent's fiscal second-quarter earnings report, which showed that total revenues grew 16 percent and that a net loss in the prior-year period swung to a profit in the current quarter.

The lines, which Agilent divested in order to receive European Commission approval for its $1.5 billion acquisition of Varian, will form the core of Bruker's new Chemical Analysis Division.

Bruker has completed its acquisition of three product lines from Varian, which it expects will "perfectly complement" its portfolio of mass spectrometry products.

Agilent completed the $1.5 billion deal after receiving confirmation from regulatory bodies that it had met the conditions required for the acquisition.

The $1.5 billion acquisition was announced almost a year ago, but its completion has been held up by regulatory bodies in the US and EU.

Pages

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.